Begrivac

Phase 3Biologic

Novartis

Begrivac is one of 97 biologic programs targeting HIV-1 infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1 InfectionActive, not recruiting

Diabetes MellitusActive, not recruiting

InfluenzaActive, not recruiting

HIV-1 InfectionPhase 3

Active, not recruiting

Diabetes MellitusPhase 3

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Begrivac

Novartis

Phase 3

1 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Crestor

AstraZeneca

Preclinical

1 5

Trexall

Alnylam Pharmaceuticals

Preclinical

1 6

Avigan

AAppili Therapeutics Inc.

Preclinical

6 7

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 8

COMIRNATY

Pfizer

Preclinical

1 9

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 10

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV-1 infection1 trial

Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

Completed·CChiltern Pesquisa Clinica Ltda·Phase 3·NCT01032408·154 enrolled

Influenza1 trial

Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Completed· Novartis logo

Novartis·Phase 3·NCT01147081·142 enrolled

Diabetes Mellitus1 trial

Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Completed·CChiltern Pesquisa Clinica Ltda·Phase 3·NCT01032395·342 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Begrivac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Begrivac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Begrivac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Novartis

Begrivac

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV-1 infection1 trial

Influenza1 trial

Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News